+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Simulations Plus Inc (SLP) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 50 Pages
  • January 2025
  • GlobalData
  • ID: 4189025
Simulations Plus Inc (SLP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Simulations Plus Inc (Simulations Plus) provides advanced software and consulting services to the biopharma industry. The company specializes in accelerating drug discovery, development, and commercialization through innovative, science-based solutions. Its product portfolio includes a range of software products for modeling, simulation, and data analysis, helping clients optimize drug development processes, reduce costs, and enhance regulatory compliance. The company also offers a comprehensive platform covering the entire drug development value chain. It provides adaptive learning solutions and medical communications services to support clinical trial success and post-regulatory commercialization. Simulations Plus is headquartered in Lancaster, California, the US.

Simulations Plus Inc Key Recent Developments

  • Jan 13, 2025: Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
  • Nov 13, 2024: Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
  • Oct 30, 2024: Simulations Plus and Partners Awarded New FDA Grant to Validate in Vitro-in Vivo Extrapolation Methods for Complex Formulations
  • Oct 23, 2024: Simulations Plus Announces Q4 and Fiscal 2024 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Simulations Plus Inc - Key Facts
  • Simulations Plus Inc - Key Employees
  • Simulations Plus Inc - Key Employee Biographies
  • Simulations Plus Inc - Major Products and Services
  • Simulations Plus Inc - History
  • Simulations Plus Inc - Company Statement
  • Simulations Plus Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Simulations Plus Inc - Business Description
  • Business Segment: Services
  • Overview
  • Performance
  • Business Segment: Software
  • Overview
  • Performance
  • Geographical Segment: Asia Pacific
  • Performance
  • Geographical Segment: EMEA
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Simulations Plus Inc - Corporate Strategy
  • Simulations Plus Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Simulations Plus Inc - Strengths
  • Simulations Plus Inc - Weaknesses
  • Simulations Plus Inc - Opportunities
  • Simulations Plus Inc - Threats
  • Simulations Plus Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Simulations Plus Inc, Medical Equipment, Deals By Year, 2019 to YTD 2025
  • Simulations Plus Inc, Medical Equipment, Deals By Type, 2019 to YTD 2025
  • Simulations Plus Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jan 13, 2025: Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
  • Nov 13, 2024: Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
  • Oct 30, 2024: Simulations Plus and Partners Awarded New FDA Grant to Validate in Vitro-in Vivo Extrapolation Methods for Complex Formulations
  • Oct 23, 2024: Simulations Plus Announces Q4 and Fiscal 2024 Results
  • Oct 09, 2024: Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
  • Aug 01, 2024: Simulations Plus Releases Dilisym X
  • Jun 18, 2024: Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
  • May 22, 2024: Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
  • Apr 04, 2024: U.S. FDA Renews DILIsym Software Licenses for 7th Year
  • Jan 09, 2024: Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Simulations Plus Inc, Key Facts
  • Simulations Plus Inc, Key Employees
  • Simulations Plus Inc, Key Employee Biographies
  • Simulations Plus Inc, Major Products and Services
  • Simulations Plus Inc, History
  • Simulations Plus Inc, Subsidiaries
  • Simulations Plus Inc, Key Competitors
  • Simulations Plus Inc, Ratios based on current share price
  • Simulations Plus Inc, Annual Ratios
  • Simulations Plus Inc, Interim Ratios
  • Simulations Plus Inc, Medical Equipment, Deals By Year, 2019 to YTD 2025
  • Simulations Plus Inc, Medical Equipment, Deals By Type, 2019 to YTD 2025
  • Simulations Plus Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Simulations Plus Inc, Performance Chart (2020 - 2024)
  • Simulations Plus Inc, Ratio Charts
  • Simulations Plus Inc, Medical Equipment, Deals By Year, 2019 to YTD 2025
  • Simulations Plus Inc, Medical Equipment, Deals by Type, 2019 to YTD 2025

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Metrum Research Group LLC
  • Optibrium Ltd
  • Veeva Systems Inc
  • ICON Plc
  • Certara Inc
  • WCG Clinical Inc